Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALTER-S006: Anlotinib Maintenance in Advanced Soft Tissue Sarcoma
NCT03890068Phase 2Completed
- Sponsor
- Sun Yat-sen University
- Start
- Apr 2019
- Primary completion
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of anlotinib in soft tissue sarcoma (STS), sponsored by Sun Yat-sen University. Primary endpoint: Progression-Free Survival up to 24 months. Started Apr 2019; status: completed.
02
Drugs
anlotinib
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT03890068.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03890068.